Clinical Trials Browser

Approved for marketing × abemaciclib × Clear all

NCT03763604 2024-12-16

Named Patient Use Program to Provide Abemaciclib (LY2835219) for the Treatment of Metastatic Breast Cancer

Approved for marketing

Breast Neoplasms

NCT02792725 2017-10-31

Expanded Access Program to Provide Abemaciclib (LY2835219) for the Treatment of Metastatic Breast Cancer

Approved for marketing

Breast Neoplasms